FDA Approves Daxxify, a Botox Competitor

Big news for medspa owners and patients: DAXXIFY™ (DaxibotulinumtoxinA-lanm), a rival of Botox®, was approved by the FDA on September 7, 2022. Like its competitor, Botox, Daxxify is a facial injection for the “temporary improvement of moderate to severe frown lines (glabellar lines) in adults.”- Daxxify.

The Wall Street Journal says, “Analysts say the drug, from Revance Therapeutics, poses a threat to the market-dominating anti-wrinkle treatment because it promises to last longer.”

The aesthetic medical industry is both excited and intrigued to witness a new facial injectable option enter the market. The hype of Daxxify’s long-lasting results presents an attractive alternative to some regular users of Botox.

“Finally, the first and only peptide-powered, FDA-approved frown line treatment with a median duration of 6 months and up to 9 months for some patients” – Daxxify
Learn more in the Press Release by Revance Therapeutics.

“‘Users do not have to go [to their medspa] once every three months. In a world where time is of the essence, having a product with a long duration factor is extremely useful.’” – Dr. Balaji Prasad said in The New York Times’ article announcing Daxxify’s FDA approval.

While some medspa patients are excited for the prospect of spacing out their injectable appointments from three to six or more months, some medspa owners are busy brainstorming their marketing strategy to cater to some patients that will be coming in twice a year versus three or four times. Acara’s marketing agency recommends enticing patients with monthly specials, which may include bundle discounts and referral promotions.

Contact us today to learn how Acara Partners can provide marketing strategy and management consulting to your medspa or aesthetic medical practice.